Q3 2021 Investor Relations Results
Participants
Financial review
Conclusion
Appendix
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
Novartis pipeline in Phase 3
Oncology
Code
Name
Mechanism
Indication(s)
mCRPC, pre-taxane
AAA617
177 Lu-PSMA-617
Radioligand therapy target PSMA
Metastatic hormone sensitive prostate cancer (mHSPC)
AAA6011) LutatheraⓇ
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
BCR-ABL inhibitor
tumors (GEP-NET 1L G3)
Chronic myeloid leukemia, 1st line
References
Innovation: Clinical trials
8 lead indications
Lead indication
Neuroscience
Code
AMG334 AimovigⓇ
BAF312 MayzentⓇ
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 KesimptaⓇ
Name
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Multiple sclerosis, pediatrics
ABL001
asciminib
ACZ885
canakinumab
IL-1b inhibitor
BYL719
CTL019
Piqray®
KymriahⓇ
PI3Ka inhibitor
Non-small cell lung cancer (NSCLC), 1L
HER2+ adv BC
NSCLC, adjuvant
Triple negative breast cancer Ovarian cancer
Code
CD19 CAR-T
DRB436
Tafinlar® +Mekinist®
BRAF inhibitor + MEK inhibitor
1L high risk acute lymphocytic leukaemia, pediatrics & young adults
Thyroid cancer
Respiratory & Allergy
Name
IGE025 XolairⓇ
QGE031 ligelizumab
Mechanism
IgE inhibitor
Indication(s)
Food allergy
Auto-injector
IgE inhibitor
Food allergy
ETB115
PromactaⓇ
Thrombopoietin receptor (TPO-R) r/r Severe aplastic anemia
agonist
INC280
Tabrecta®
Met inhibitor
Non-small cell lung cancer
Cardiovascular, Renal, Metabolism
JDQ443 JDQ443
KRAS inhibitor
LEE011
Kisqali®
CDK4 Inhibitor
LNP023
iptacopan
CFB inhibitor
MBG453
NIS793
sabatolimab
NIS793
TIM3 antagonist
TGFB1 inhibitor
VDT482
tislelizumab
PD1 inhibitor
YTB323
YTB323
CD19 CAR-T
Immunology, Hepatology, Dermatology
2/3L Non-small cell lung cancer
HR+/HER2- BC (adj)
Paroxysmal nocturnal haemoglobinuria
Myelodysplastic syndrome
Pancreatic cancer
1L Nasopharyngeal Carcinoma
1L ESCC
1L Hepatocellular Carcinoma
1L Bladder Urothelial Cell Carcinoma
2L r/r Diffuse large B-cell lymphoma
1L Gastric cancer
Code
Name
Mechanism
KJX839 Leqvio®
LCZ696 Entresto®
siRNA (regulation of LDL-C)
Angiotensin receptor/neprilysin
inhibitor
CVRR-LDLC
Hyperlipidemia, pediatrics
Congestive heart failure, pediatrics²)
LNP023
iptacopan
CFB inhibitor
Non-small cell lung cancer
Localized ESCC
TQJ230 Pelacarsen
ASO targeting Lp(a)
C3 glomerulopathy
Atypical haemolytic uraemic syndrome
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
1L Small Cell Lung Cancer
Indication(s)
IgA nephropathy
Code
Name
Mechanism
Indication(s)
Lupus Nephritis
AIN457
Cosentyx®
IL17A inhibitor
QGE031
ligelizumab
remibrutinib
LOU064
IgE inhibitor
BTK inhibitor
1. 177 Lu-dotatate in US. 2. Approved in US.
Psoriatic arthritis (IV formulation)
Ankylosing spondylitis (IV formulation)
Giant cell arteritis
Chronic spontaneous urticaria
Chronic inducible urticarial (CINDU)
Chronic spontaneous urticaria
Biosimilars
Code
Name
GP2411 denosumab
SOK583 aflibercept
Mechanism
anti RANKL mAb
VEGF inhibitor
AS H2H
Hidradenitis suppurativa
Ophthalmology
Code
Name
RTH258 BeovuⓇ
Mechanism
VEGF inhibitor
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
Indication(s)
Diabetic retinopathy
Global Health
Code
COA566
Name
Coartem®
Mechanism
Indication(s)
Malaria, uncomplicated (<5kg patients)
55 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation